Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Target protein of Yimusake tablet acting on abnormal balham syndrome and erectile dysfunction syndrome models and screening method thereof

A screening method and protein technology, applied in the biological field, can solve problems such as unreported targets, lack of theory and application guidance, and unclear mechanism of action

Active Publication Date: 2017-03-29
XINJIANG MEDICAL UNIV
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Guided by the syndrome differentiation and treatment system of Uyghur medicine, it is widely used in Uygur medicine clinics, and it has also been used in clinical andrology in major hospitals inside and outside Xinjiang. It lacks theoretical and practical guidance in the use of modern medicine (Western medicine) hospitals, and cannot better serve patients of all nationalities across the country

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Target protein of Yimusake tablet acting on abnormal balham syndrome and erectile dysfunction syndrome models and screening method thereof
  • Target protein of Yimusake tablet acting on abnormal balham syndrome and erectile dysfunction syndrome models and screening method thereof
  • Target protein of Yimusake tablet acting on abnormal balham syndrome and erectile dysfunction syndrome models and screening method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] 1. Modeling and grouping

[0114] 25 sexually mature female mice were selected and raised under normal conditions after castration, and were used for mating experiments. Male rats were mated with female rats in estrus and combined with APO erection test to confirm that they had normal sexual function (those without normal sexual function were eliminated), and 50 rats were taken to enter the experiment, and 10 rats were randomly selected from them as normal The control group was raised in a normal environment with a temperature of 18-22°C, and the relative humidity of the environment was 40-60%. Modeling was carried out in a climate box, set temperature: 8-12°C, humidity 70-80%, fed alternately day and night for 12 / 12 hours, and placed in the same feeding environment as the normal group for other times. When the rats in the model group have dull skin and hair, lack of luster; tiredness, lying down and less movement; sensitive to stimulation, like to get together, lethar...

Embodiment 2

[0150] ELISA Detection of Drug Target Proteins in Yimusak Tablets

[0151]1) ELISA detection of the serum candidate protein of Yimusake Tablets in the rat model of abnormal mucus syndrome

[0152] Randomly select 5 kinds of serum candidate differential proteins, and perform ELISA detection on the rat model serum of the normal control group, syndrome group, and syndrome drug group, to verify whether the serum candidate differential proteins of the present invention can be used as Yimusake Tablets to challenge abnormal mucus. Drug target markers in rats:

[0153] That is, randomly select and detect No. 1 protein P01015 (angiotensinogen); No. 3 protein P02764 (α-1-acid glycoprotein); No. 4 protein P02767 (transthyretin); protein binding protein) and protein No. 14 P26644 (β2 glycoprotein 1). Double-antibody sandwich ELISA kits were used respectively (rat angiotensinogen (AGT) double-antibody sandwich kit: Wuhan USS Co., Ltd.; rat α1 acid glycoprotein (α1AG) double-antibody sand...

Embodiment 3

[0169] Immunohistochemical Detection of Drug Target Proteins in Yimusake Tablets

[0170] Randomly select 4 kinds of candidate differential proteins in penile smooth muscle tissue, and perform immunohistochemical detection on the penile smooth muscle of abnormal mucus type impotence syndrome rats, disease syndrome drug group rats and normal control group rats, to verify the protein in the tissue of the present invention Whether the candidate differential protein can be used as a drug target marker for Yimusak tablet in penile smooth muscle tissue of rats with abnormal mucus type impotence syndrome:

[0171] That is, protein No. 4 P02625 (parvalbumin α); protein No. 15 Q9Z2L0 (voltage-dependent anion-selective channel protein 1); protein No. 26 P47853 (bischain) and protein No. P04904 (glutathione S-transferase α-3); use the antibodies of the above proteins respectively (all antibodies are purchased from Abcam (Shanghai) Trading Co., Ltd.), and treat the normal control group, d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides medicine target protein of serums after a Yimusake tablet acts on rats with an abnormal balham syndrome and an abnormal Balham type erectile dysfunction disease, and a penis smooth muscle tissue, and a screening method thereof. The method comprises the following steps of 1, providing a normal comparison set, a syndrome set, a syndrome medicine set, a disease set and a disease medicine set; 2, collecting whole blood, separating the serum and the penis smooth muscle tissue from the whole blood; 3, extracting the protein; 4, purifying after marking; 5, acquiring a fingerprint spectrum after spectrum detection, analyzing protein compositions after screening, and acquiring each set of serums and the penis smooth muscle tissue protein; and 6, acquiring a Yimusake tablet action target protein system by making statistics, comparing and screening. According to the protein and the screening method of the protein provided by the invention, the action target of the uigur medicine, the Yimusake tablet, on the abnormal Balham type erectile dysfunction in uigur medicine is clear, and a foundation is laid for further disclosure of the action mechanism of the Yimusake tablet and new and secondary development of the Yimusake tablet.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a target protein and a screening method for Yimusak tablets acting on abnormal mucus syndrome and impotence syndrome models. Background technique [0002] Uighur medicine (Uyghur medicine) is an important part of the traditional medicine of the motherland. Uighur medicine humor theory believes that the human body is composed of 4 kinds of humors: biliary, bloody, phlegmatic and black gallbladder. The dynamics of the above four kinds of humoral Balance is the physiological basis of a healthy body, and a change in the quantity or / and quality of a certain body fluid quality will cause the imbalance of body fluid quality and produce an abnormal body fluid quality syndrome (syndrome), which has a causal relationship with the occurrence of various diseases. Humoral pathology (humoral theory) is the basis of Uygur medicine theory. It believes that among the four kinds of body flu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/6848G01N33/6893G01N2333/47G01N2333/4722G01N2333/765G01N2333/805G01N2333/811G01N2333/902G01N2333/90203G01N2333/91G01N2333/912G01N2333/91235G01N2333/918G01N2333/988G01N2333/99
Inventor 阿地力江·伊明
Owner XINJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com